537 related articles for article (PubMed ID: 17335296)
1. Use of sirolimus in solid organ transplantation.
Augustine JJ; Bodziak KA; Hricik DE
Drugs; 2007; 67(3):369-91. PubMed ID: 17335296
[TBL] [Abstract][Full Text] [Related]
2. Sirolimus in solid organ transplantation: current therapies and new frontiers.
Veroux M; Tallarita T; Corona D; D'Assoro A; Gurrieri C; Veroux P
Immunotherapy; 2011 Dec; 3(12):1487-97. PubMed ID: 22091684
[TBL] [Abstract][Full Text] [Related]
3. Benefit-risk assessment of sirolimus in renal transplantation.
Kuypers DR
Drug Saf; 2005; 28(2):153-81. PubMed ID: 15691225
[TBL] [Abstract][Full Text] [Related]
4. Safety of mTOR inhibitors in adult solid organ transplantation.
Ventura-Aguiar P; Campistol JM; Diekmann F
Expert Opin Drug Saf; 2016; 15(3):303-19. PubMed ID: 26667069
[TBL] [Abstract][Full Text] [Related]
5. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
6. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
Gabardi S; Baroletti SA
Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
[TBL] [Abstract][Full Text] [Related]
7. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
[TBL] [Abstract][Full Text] [Related]
8. Considerations in sirolimus use in the early and late post-transplant periods.
Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
[TBL] [Abstract][Full Text] [Related]
9. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
10. Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: effect on renal function and proteinuria.
Morales J; Fierro A; Benavente D; Zehnder C; Ferrario M; Contreras L; Herzog C; Buckel E
Transplant Proc; 2007 Apr; 39(3):591-3. PubMed ID: 17445551
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus in pediatric renal transplantation.
Kasap B
Pediatr Transplant; 2011 Nov; 15(7):673-85. PubMed ID: 22004542
[TBL] [Abstract][Full Text] [Related]
12. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
Fernandes-Silva G; Ivani de Paula M; Rangel ÉB
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):367-385. PubMed ID: 27659512
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.
Fine NM; Kushwaha SS
Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747
[TBL] [Abstract][Full Text] [Related]
14. Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.
Kahan BD
Transplant Proc; 2008 Dec; 40(10 Suppl):S17-20. PubMed ID: 19100899
[TBL] [Abstract][Full Text] [Related]
15. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
Franco-Esteve A; Tordera D; de la Sen ML; Jiménez L; Mas P; Muñoz C; Olivares J
Nefrologia; 2012; 32(5):631-8. PubMed ID: 23013949
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus-based immunosuppression: present state of the art.
Kahan BD
J Nephrol; 2004; 17 Suppl 8():S32-9. PubMed ID: 15599884
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus: a new agent for prevention of renal allograft rejection.
Vasquez EM
Am J Health Syst Pharm; 2000 Mar; 57(5):437-48; quiz 449-51. PubMed ID: 10711524
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus: continuing the evolution of transplant immunosuppression.
Ingle GR; Sievers TM; Holt CD
Ann Pharmacother; 2000 Sep; 34(9):1044-55. PubMed ID: 10981252
[TBL] [Abstract][Full Text] [Related]
20. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
